Prospective Multicenter Non-interventional Study in Patients With Knee or Hip Osteoarthritis Having a Theraflex Treatment

Launched by BAYER · Oct 31, 2017

Keywords

ClinConnect Summary

Other information that is planned for evaluation in this study includes consumption of Theraflex, intake of analgesics for joint pain relief and description of basic patient characteristics such as age, weight and body mass index and others.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients 45 to 75 years with Hip or Knee OA stage I to III
• • Patient started current treatment with Theraflex not more than 2 weeks prior to inclusion into the study
• • Personally signed and dated informed consent
• Exclusion Criteria:
• • Patients participating in an investigational program with interventions outside of routine clinical practice
• • Patients with Hip or Knee OA stage 0 or stage IV
• • Patients who have both Hip and Knee OA and OA of any other location
• • Contraindications for use of Theraflex in accordance with approved label(known hypersensitivity, severe chronic renal failure)
• • Females who are pregnant or breastfeeding
• • Patients who completed a treatment with Theraflex or another combination of Gl+ Ch less than 5 months before start of the current treatment
• • Patients who completed intra-articular corticosteroids treatment in the last 3 months to exclusion criteria
• • Patients who completed hyaluronic injections of the lower limbs in the last 6 months